12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

XEN-D0501: Phase I data

A double-blind, placebo-controlled, crossover Phase I trial in healthy volunteers showed that oral XEN-D0501 was well tolerated at doses of up to twice-daily 5...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >